MichaelYoon-SukChoiMD
Gastroenterology • Boston, MAAssistant Professor, Medicine, Massachusetts General Hospital, Harvard Medical School
Dr. Choi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit Street Blk 4
Gastroenterology Associates
Boston, MA 02114Phone+1 617-724-6006Fax+1 617-724-6832- Is this information wrong?
Education & Training
Dana-Farber Cancer Institute2003 - 2008
Massachusetts General HospitalFellowship, Gastroenterology, 2000 - 2005
University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
Weill Cornell MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
ME State Medical License 2010 - 2025
MA State Medical License 2003 - 2024- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.Cheng Sun, Chan Zhou, Kaveh Daneshvar, Amel Ben Saad, Arcadia J Kratkiewicz, Benjamin J Toles, Nahid Arghiani, Anja Hess, Jennifer Y Chen, Joshua V Pondick, Samuel R Y...> ;Hepatology. 2024 Apr 2
- 23 citationsA role for intestinal alkaline phosphatase in preventing liver fibrosis.Yang Liu, Paul M Cavallaro, Byeong-Moo Kim, Tao Liu, Hongyan Wang, Florian Kühn, Fatemeh Adiliaghdam, Enyu Liu, Robin Vasan, Ehsan Samarbafzadeh, Matthew Z. Farber, Ju...> ;Theranostics. 2021 Jan 1
- Author Correction: Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosisByeong-Moo Kim, Ahmed Maher Abdelfattah, Robin Vasan, Bryan C. Fuchs, Michael Y. Choi> ;Scientific Reports. 2020 Jun 19
- Join now to see all
Lectures
- A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Enzyme Treatment Reduces Alcohol-Induced Liver Damage in Mouse ModelsApril 25th, 2017
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Lawrence General HospitalLawrence, Massachusetts
UMass Memorial Medical CenterWorcester, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
